|Bid||133.10 x 1100|
|Ask||144.32 x 1300|
|Day's Range||131.83 - 139.22|
|52 Week Range||131.47 - 249.42|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 23, 2022 - Feb. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||220.08|
Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
The CHMP gives a positive opinion on, and recommends approval to Amgen's (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.